AstraZeneca's lung cancer drug shows promise in passing Phase III trial

Caitlin Wilson | | Health Exec | Precision Medicine

According to a statement released by British drug-maker AstraZeneca July 18, the company’s new lung cancer drug is on the right track for government approval.

The drug, Tagrisso, underwent a 419-person, multinational randomized Phase III trial and came out “demonstrating superior progression-free survival compared to standard platinum-based doublet chemotherapy.”

The drug is a second-line treatment for patients with non-small cell lung cancer whose disease hasn’t responded to first-line treatments. It is especially targeted for patients with a specific mutation, EGFRm, to help slow tumor growth.

According to the company’s statement, the drug also did better than chemotherapy in objective response rates, disease control rate and duration of response.

Clinical trials of Tagrisso will continue to fully determine the drug’s effectiveness, according to AstraZeneca. As Reuters pointed out, sales from this drug could help make up lost revenue from expiring patents on other drugs. 

Caitlin Wilson,

Senior Writer

As a Senior Writer at TriMed Media Group, Caitlin covers breaking news across several facets of the healthcare industry for all of TriMed's brands.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Cardiovascular Business
Cardiology groups cheer new bill that would improve access to Medicare claims data

If passed, this bill would help clinician-led clinical registries explore Medicare data for research purposes. The Society of Thoracic Surgeons and American College of Cardiology both shared public support for the bipartisan legislation. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup